Sign in

CIK 0001434316

  • Non-accelerated filer
  • Smaller reporting company

FATE THERAPEUTICS INC

Sign in to watch
Ticker
FATE
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
651311552
Phone
+1 858-875-1803
Business address
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA, 92131
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$13,525
in 1 filing

Net −$13,525. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Adawi Kamal −$14K Chief Financial Officer sold 7% of stake

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2022-01-10 Wolchko J Scott President and CEO Sale −20,894 $47.17 $986K 446,213
2022-01-10 Wolchko J Scott President and CEO Sale −101 $47.72 $5K 446,112
2022-01-10 TAHL CINDY General Counsel and Secretary Sale −7,095 $46.37 $329K 161,911
2022-01-10 TAHL CINDY General Counsel and Secretary Sale −643 $47.15 $30K 161,268
2022-01-10 Valamehr Bahram Chief R&D Officer Sale −5,245 $46.33 $243K 151,453
2022-01-10 Valamehr Bahram Chief R&D Officer Sale −351 $47.17 $17K 151,102
2022-01-03 TAHL CINDY General Counsel and Secretary Option exercise +50,000 $6.55 $328K 219,006
2022-01-03 TAHL CINDY General Counsel and Secretary Sale −4,427 $57.76 $256K 214,579
2022-01-03 TAHL CINDY General Counsel and Secretary Sale −16,900 $58.84 $994K 197,679
2022-01-03 TAHL CINDY General Counsel and Secretary Sale −27,812 $59.86 $1.7M 169,867
2022-01-03 TAHL CINDY General Counsel and Secretary Sale −861 $60.31 $52K 169,006
2022-01-03 TAHL CINDY General Counsel and Secretary Option exercise · Stock Option (Right to Buy) −50,000 66,643
2021-12-20 Dulac Edward J III Chief Financial Officer Option exercise +14,437 $35.52 $513K 126,381
2021-12-20 Dulac Edward J III Chief Financial Officer Sale −15,977 $60.00 $959K 110,404
2021-12-20 Dulac Edward J III Chief Financial Officer Option exercise · Stock Option (Right to Buy) −14,437 128,238
2021-12-13 Valamehr Bahram Chief R&D Officer Option exercise +25,000 $2.73 $68K 181,698
2021-12-13 Valamehr Bahram Chief R&D Officer Sale −2,100 $45.68 $96K 179,598
2021-12-13 Valamehr Bahram Chief R&D Officer Sale −7,018 $46.72 $328K 172,580
2021-12-13 Valamehr Bahram Chief R&D Officer Sale −6,564 $47.61 $313K 166,016
2021-12-13 Valamehr Bahram Chief R&D Officer Sale −7,718 $48.75 $376K 158,298

Page 14 of 26 · 503 trades